chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Encounter for electrocardiogram. Hospital admission within 6 weeks of receiving the COVID vaccine.
A report has been received from a Health Professional concerning a 10 year old. Male subject who had been receiving Nasal FLUMIST (INTRANASAL) started on 24-Jan-2014. ADMINISTRATION OF EXPIRED DOSE was reported. The outcome of the event of ADMINISTRATION OF EXPIRED DOSE is unknown. The report was considered to be non-serious by the reporter.
Follow-up report received from a physician on 01 Mar 2010: This patient received a 0.5 mL IM dose of FLUVIRIN (batch no. 10073802) on 01 Mar 2010 that expired in Jan 2010. No adverse effects were noted due to administration of the vaccine. After an internal review done on 08 May 2010 to the information received on 01 Mar 2010, the following significant correction was made: The suspect product FLUVIRIN was recoded to S-OIV FLUVIRIN.
Left arm redness, pain, warmth, swelling, and induration for 24 hours after vaccines.
Information has been received from a 67 year old female with "little" herpes on her left hip and allergy to topical Lidocaine and morphine (makes her nauseous) who on 22-MAR-2007 was vaccinated SC with a 0.65 ml dose of Zostavax (Oka/Merck). Concomitant therapy included "DIGITEX", atenolol and ezetimibe (MSD). On approximately 14-JUN-2007 the patient developed shingles on her left hip. The patient believed that vaccination with Zostavax (Oka/Merck) turned her hip herpes into shingles. After patient developed shingles, she was hospitalized for "unrelated heart problems" and the hospital staff put a sign on her door saying that anyone who has not had chickenpox should not enter her room because her case was "so severe". It was stated that the patient was not hospitalized for shingles. At the time of the report the patient had not recovered. No diagnostic laboratory tests were undertaken. A product quality complaint was not involved. Additional information has been requested.
PATIENT STATED THAT APPROXIMATELY 26 HOURS AFTER HIS INJECTION HE WAS INCOHERENT, FELL, AND COULD NOT MOVE. ADVERSE EVENT LASTED 24 HOURS.
experienced COVID-19 pneumonia; experienced COVID-19 pneumonia; This is a spontaneous report received from a contactable reporter(s) (Other HCP).  A 73-year-old female patient received BNT162b2 (BNT162B2), on 16Mar2021 as dose 1, single (Batch/Lot number: unknown) and on 06Apr2021 as dose 2, single (Batch/Lot number: unknown) at the age of 72 years for covid-19 immunisation. The patient's relevant medical history included: "Osteopenia" (unspecified if ongoing), notes: Osteopenia, unchanged osteolytic lesions, and unchanged vertebral compression fracture deformities; "osteolytic lesions" (unspecified if ongoing), notes: Osteopenia, unchanged osteolytic lesions, and unchanged vertebral compression fracture deformities; "vertebral compression fracture deformities" (unspecified if ongoing), notes: Osteopenia, unchanged osteolytic lesions, and unchanged vertebral compression fracture deformities. The patient's concomitant medications were not reported.  The following information was reported: VACCINATION FAILURE (hospitalization, medically significant) with onset 28Jan2022, outcome "unknown", COVID-19 PNEUMONIA (hospitalization, medically significant) with onset 28Jan2022, outcome "recovered" (02Feb2022) and all described as "experienced COVID-19 pneumonia". The patient was hospitalized for covid-19 pneumonia (start date: 28Jan2022, discharge date: 02Feb2022, hospitalization duration: 5 day(s)). The patient underwent the following laboratory tests and procedures: Chest X-ray: (28Jan2022) Patchy bibsilar airspace opacity concerning for pn, notes: Patchy bibsilar airspace opacity concerning for pneumonia; Computerised tomogram: (28Jan2022) New multifocal pneumonia 2., notes: New multifocal pneumonia 2. Osteopenia, unchanged osteolytic lesions, and unchanged vertebral compression fracture deformities. CT Chest without IV Contract.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: The reported COVID-19 pneumonia after both the doses of COVID-19 immunization is considered as vaccination failure of BNT162B2, and the Company cannot completely exclude the possible causality between the reported events and BNT162B2 administration.
Rash upper arm and shoulder across the back, also on left side of chest. Hives were on outer and inner surface of upper left arm, pain on inner side of upper left arm.
thrombocytopenia (platelet = 10,000) with no signs of bleeding (only petechiae)
Pt recv vax on 8/28/98; on 9/2/98 pt exp red, blotchy rash that began on face, spread down torso over 3 dy period w/ itching.  Pt tx= Benadryl.
got weird reactions for many days, as if I had the flu; Initial information received on 20-Oct-2022 regarding an unsolicited valid non-serious case received via consumer/non-hcp. RA number: 01331257  This case involves an unknown age female patient who experienced got weird reactions for many days, as if i had the flu while receiving vaccine INFLUENZA VACCINE.   The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.    On an unknown date 8 to 10 years ago, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer at (unknown: formulation, strength, dose, route, lot number, administration site) for flu vaccination.  On an unknown date, the patient developed a non-serious got weird reactions for many days, as if i had the flu (influenza like illness) at unknown latency following the administration of INFLUENZA VACCINE.  It was reported that She has not received a flu shot in 8 to 10 years due to her reactions the last time she received a flu shot. It was 8 to 10 years ago, and she received influenza vaccine. She does not know the manufacturers "senior" vaccine that she received. She stated that she "got weird reactions for many days, as if I had the flu". Another year she received an influenza vaccine that was egg-free. She does not know the particular manufacturer of the egg-free flu vaccine that she received; and has no way to find out since it was in a different state at least 10 years ago. She had a "bad reaction" to that flu vaccine without egg."     Action taken: Not applicable.  Corrective treatment: not reported.  At time of reporting, the outcome was Unknown for the event got weird reactions for many days, as if i had the flu.
This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, concomitant medication and drug reactions or allergies was reported. On 08-JUL-2014, the patient was vaccinated with a dose (the first dose in series) of GARDASIL (strength, dose, route of administration, lot # and expiration date were not provided). The office intended to have the patient complete the series of vaccination with GARDASIL 9 and on 15-SEP-2015, the patient was vaccinated with a dose (the second dose in series) of GARDASIL 9 (strength, dose, route of administration, lot # and expiration date were not provided). On 30-OCT-2015, the patient was vaccinated with a dose (the third dose in series) of GARDASIL 9 (strength, dose, route of administration, lot # and expiration date were not provided) which was given "too early". These were the only doses of GARDASIL and GARDASIL 9, this patient had received. No symptoms of adverse events were reported. The outcome of off label use was unknown. The relatedness between off label use and GARDASIL and GARDASIL 9 was not reported. Additional information has been requested.
COVID-19; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Physician). The reporter is the patient.  A 29-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 30Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 29 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 31May2022, outcome "unknown" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (31May2022) Positive; (19Jun2022) Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical Information: There were no other medications in two weeks.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on plausible dose -event relationship post vaccination and no other alternate explanation the causal role of BNT162B2 cannot be excluded for the reported LOE events
got shingles after getting his shingles vaccine/suspected vaccination failure; shingles; This case was reported by a consumer and described the occurrence of suspected vaccination failure in a male patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were reported as follows: The patient was the reporter's father. The age at vaccination was not reported. The patient got shingles after getting his shingles vaccine. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory confirmation were unknown at the time of reporting. No contact details were available. The case had been linked with US2021AMR202793, a tag post.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR202793:tag at post
6pm - Dry cough with tickle in her throat swollen glands in her neck; 630pm - Eyes became bloodshot , swollen and itchy Breathing was shallow and rapid; 830pm - Developed headache and felt chilled; 200AM - Felt "warm" and eyes were draining and had nausea; 10AM - next day - complained of headache
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 23-SEP-2014 the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 (strength: 05ml, lot # K005957, expiration date 08-MAR-2015, route unspecified). This specified lot number vaccine was exposed to temperature excursion once. The total cumulative excursion time was 2490 hours with lowest recorded temperature of 20 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effect reported. This is one of several reports received from the same source. Additional information has been requested.
UNSTABLE ANGINA 11/16/2022 &  12/19/2022 -- RECURRENCE OF SAME SYMPTOMS
Nausea, headache, fatigue (felt like an extreme hangover). Started about 12 hours after vaccine and lasted 24 hours.
On 1/5/21 I developed chills, body aches, and a sore arm. As of 1/6/21 the chills and body aches have stopped.
Patient with history of diabetes. He was brought to the ED by EMS on 12/16/22 for evaluation of hyperglycemia and weakness. Initially, patient's blood glucose was greater than 700 with severe acidosis and hypotension. COVID PCR preformed in the ED resulted positive. He was admitted 12/16/22 for diabetic ketoacidosis. Additionally, sputum and blood cultures grew Staph aureus. Patient's condition continued to deteriorate, and ultimately family decided to pursue comfort cares. Patient was extubated 12/22/22 and passed away that day.  Discharge diagnoses include COVID pneumonia, diabetic ketoacidosis, and severe sepsis with septic shock, among other diagnoses.
Unstable angina . ED visit to hospital admission. This visit was within 6 weeks of receiving the COVID vaccine.
This spontaneous report as received from a non pregnant 37 years old female pharmacist refers to herself. The pharmacist had no pertinent medical history, drug reactions or allergies. On 25-MAR-2014 the pharmacist was vaccinated with a dose of RECOMBIVAX HB (therapy type not reported) 0.5 ml, intramuscular (lot # J008506, expiry date 07-FEB-2016, reported as 04-FEB-2016). The pharmacist did not take any concomitant medications. On an unknown date, in 2014 (reported as "a few weeks ago") the pharmacist experienced some initial vomiting, fatigue, stomach cramps all week. The pharmacist stated on an approximately 05-APR-2014 (reported as "this weekend") she had chills, night sweats and problems focusing on near objects, presbyopia, She also stated that gastrointestinal symptoms subsided (date unspecified, in 2014) but the vision was still a concern. The pharmacist also stated that currently she was experiencing dizziness with the difficulty with vision and focus along with periodic waves of heat. The pharmacist was unsure if she should have second dose in series. There were no lab diagnostic studies performed. There was no treatment given for adverse events. The pharmacist did not seek medical attention. The outcome of night sweats, fatigue and chills was not reported. The relatedness between all events and RECOMBIVAX HB was not reported. Additional information has been requested.
The patient developed high fevers, profound watery diarrhea up to 13L/day, requiring IV administration of replacement fluids. He ultimately developed ARDS and succumbed to this illness.
This spontaneous report as received from a registered nurse refers to a female patient of unknown age. The patient's medical history included chemotherapy. On an unknown date, the patient was vaccinated with a dose of ZOSTAVAX (dose, route and lot # not reported). The nurse reported that the patient received ZOSTAVAX one month after she completed chemotherapy. The nurse also reported that the patient developed shingles six weeks after receipt of the vaccine. At the time of the report, the patient's outcome was unknown. Additional information has been requested.
Approx. thirty minutes after client received all vaccines listed above I observed client's nose bleeding from left nostril.  I pinched nostril and his mother applied a cold compress.  When I asked the child to blow his nose, he did and we observed that the bleeding had stopped.  I advised his mother to take him to emergency since she refused EMS.  I called the morning of 03/04/2022 to inquire about the client.  His mother said she took him to ER and he was released without any follow-up or medications.
Local reaction to PCV 13 (L) deltoid E 60 x 60 mm. I 30 x 35 mm. Tactile temperature. Irritable.
Blanchable slightly raised erythematous rash covering most of the body with some coalescence.
Information has been received from a nurse concerning her daughter, an 18 year old female who on approximately 26-DEC-2007 was vaccinated with a first dose of GARDASIL vaccine (yeast) (route and administrating site not reported). The patient experienced soreness, redness and swelling in her arm as well as a fever that lasted for a few days. It was noted that the patient did not feel well for a period of approximately one week. Subsequently, the patient recovered from soreness, redness and swelling in her arm and fever. Additional information has been requested.
This spontaneous report as received from a Healthcare worker refers to a patient of unknown age and gender. On 08-MAY-2013 the patient was vaccinated with third dose of GARDASIL (lot # 668261/1397AA, exp date 09-APR-2013) injection, 0.5 mL, intramuscular. Healthcare worker reported that the first dose of GARDASIL was administered on 07-NOV-2012 and the second dose was administered on 07-JAN-2013. No adverse effect reported. Additional information has been requested.
Employee reports hives on both arms, both legs, & both feet starting the same day after she received the Tdap. Pain at site of injection, very tired, headache, no itching. Saw PCP given BENADRYL & cortisone medication.
Vaccine administered 11-12-03, hospitalized      11-19-03 for difficulty breathing,weight loss, diagnosis of bronchiolitis and put on oxygen for two days.  Noticed first head tick/seizure 11-29-03. Office visit with the pediatrician and referred to neurologist who ordered EEG which gave diagnosis of seizures/partial complex seizures.  Put on Lamictal to control seizures, had to discontinue because of allergic reaction.  Admitted back to the hospital on 01-18-04 for further testing and put on phenobarbitol.  Admitted back to the hospital on 03-01-04 for more testing, EEG,CT scan.
Arm is still swollen; Arm is still red; Night sweats; Nausea; Chills; This case was reported by a consumer via call center representative and described the occurrence of swelling arm in a 80-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   In July 2022, the patient received the 1st dose of Shingrix. In July 2022, less than a day after receiving Shingrix, the patient experienced swelling arm, erythema of extremities, night sweat, nausea and chills. On an unknown date, the outcome of the swelling arm, erythema of extremities, night sweat, nausea and chills were not recovered/not resolved.   It was unknown if the reporter considered the swelling arm, erythema of extremities, night sweat, nausea and chills to be related to Shingrix.     Additional Information: GSK receipt date: 29-Jul-2022 Reporter comment: This case was reported by a patient via interactive digital media. The patient received the first dose of Shingrix. After 3 days the patient still had issues with arm swollen, red, night sweats, nausea and chills. The patient want to know that was this normal and how long does it go on. Additional Supportive Information: Follow-up would not possible, as no contact, details were available.
I tested positive for COVID again; I tested positive for COVID again; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 66-year-old female patient (not pregnant) received bnt162b2, bnt162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 10Oct2022 as dose 5 (booster), single (Lot number: GH9693) for covid-19 immunisation; covid-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "History (decades ago) of thyroid ca" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 01Oct2023, outcome "not recovered" and all described as "I tested positive for COVID again". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Oct2023) Positive; (Oct2023) Negative, notes: tested negative twice this week. Therapeutic measures were taken as a result of drug ineffective, covid-19.
Redness and swelling, the size of golfball with pain at vaccine site. Temperature as high as 104 with vomiting.  9/17/09 Hospital records received DOS 8/24/09 to 8/27/09. Assessment: Left upper extremity cellulitis with early sepsis, nausea and vomiting due to drug intolerance to Bactrim.  Patient presented with left upper extremity swelling, recurrent nausea and vomiting. 10/16/09 Additional Hospital Record received, Dates of Service 8/24/09-8/27/09.  Secondary diagnoses:  Adverse effect sulfonamides, adverse effect tetanus vaccine, endocrine/nerv NEO NOS, volume depletion.   ICD:  682.3, 729.81, 787.01, E931.0, E948.4, 239.7, 276.50
Patient returns after receiving Flumist influenza vaccine.  She states that about 30 min later she felt numbness in her R cheek and lip.  She states that she has had anaphylaxis for other antibiotics, etc.  B/P 133/84 which she states is a little higher and usual.  Loratadine 10 mg given and asked her to wait in EHS for 15-20 min. 20 min later.  Patient states the area is less numb. She denies dyspnea.  BP 123/77.  Asked patient to report back to EHS should symptoms change and then seek care in ER or PCP. VAERS will be submitted.
This spontaneous report was received from a pharmacist refers to 73 years old female patient. On an unknown date, the patient was vaccinated with a dose of ZOSTAVAX (lot number, expiry date and route was not reported). On an unspecified date, the patient complained of burning sensation and stinging. The outcome of the reported events were unknown. This is one of the 8 reports received from the same reporter. Additional information is not expected.
I was seen at 21:55 on 01/19/2022 I was having atrial fibrillation. They game me some metoprolol and nothing happened. Then at 23:23 they were going to do a cardio version. They administered 60mg of Propofol and then my heart converted on its own.  I had a follow up with a cardiologist.
I get vertigo (BPPV) every time I put my head back too far. Have to do the Epley maneuver to feel better. Both ears are affected.  This is still happening.
This is a spontaneous report from a RN referring to a 41 year old male. On 5/26/99, the pt received is 1st dose of Lymerix. Approximately 10 days later, on 6/7/99, the pt experienced generalized rash, itching, shortness of breath, dizziness and hot/cold flashes. She was seen twice by a physician and treated with Medrol Cospak. The most recent information, received on 8/11/99, reports the condition of the pt is recovered.
This case was reported by a consumer (the subject's mother) and described the occurrence of high levels of mercury in an infant male subject (2 to 3 months of age) who was vaccinated with PEDIARIX, GlaxoSmithKline.  A physician or other health care professional has not verified this report.  On an unspecified date (thought to be 12 November 2004) the subject received unspecified dose (possibly the 1st dose) of PEDIARIX at 0.5 ml.  The lot number for this vaccine was thought to be 2191BA9 or 21918A9 (the lot number was difficult to read).  The mother stated that her son experienced an asthma attack three days after his "vaccinations" and he began to change.  It was reported that the subject developed encephalopathy.  He is now unable to talk, or walk and he was not able to look his mother in the eye.  The subjects urine was tested and found to contain high levels of mercury.  A urine porphorin test performed on 06 April 2008 revealed the level of heavy metals (metal toxicity) in the subjects body to be 216 (normal 0 - 153).  The events were considered by GSK to be medically significant.  The subject was seen in the emergency room.  It was reported that the subject received an unspecified GSK vaccine on 14 January 2005 with lot number 21919A9, another on 11 March 2005 with lot number AC21AD10CA and then another on 28 November 2005 with lot number AC14A006BA (lot numbers could be incorrect as they again were hard to read).  The reporter stated that it was the PEDIARIX vaccine that started her son's "injury."  At the time of reporting the outcome of the events was described as worse with the exception of encephalopathy, lack of eye contact and the asthma attack that were unspecified.  The reporter expressed concern over the amount of thimerosal in the PEDIARIX vaccine.
This is a spontaneous report from a non-contactable consumer via Pfizer colleague reported for herself. An about 65-year-old female patient received PREVNAR, in Jun2016 at 0.5 ml, single. Medical history included ongoing thyroid disorder from maybe at least five years, and ongoing type 2 diabetes mellitus. The patient's concomitant medications were not reported. The patient experienced vaccination site pain in Jun2016 with outcome of recovered. No follow-up attempts are possible. No further information is expected.